NCI-H23Homo sapiens (Human)Cancer cell line
Also known as: NCI.H23, NCI H23, H-23, H23, NCIH23, H63 (Confirmed by author personal communication.)
Quick Overview
Human cancer cell line for research on genetic and molecular mechanisms.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1547 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lung[UBERON:UBERON_0002048] |
Donor Information
| Age | 51 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | black_or_african_american |
Disease Information
| Disease | Lung adenocarcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Lung Adenocarcinoma |
| OncoTree Code | LUAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000900_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | ATM | p.Gln1919Pro (c.5756A>C) | Homozygous | - | from parent cell line NCI-H23 |
| MutationSimple | KRAS | p.Gly12Cys (c.34G>T) | Unspecified | - | PubMed=21173094 |
| MutationSimple | STK11 | p.Trp332Ter (c.996G>A) | Homozygous | - | from parent cell line NCI-H23 |
| MutationSimple | TP53 | p.Met246Ile (c.738G>C) | Homozygous | - | from parent cell line NCI-H23 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
Cancer Res. 73:4372-4382(2013).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics.
Shah P., Whiteley G.R., Zhang H.
J. Proteome Res. 17:2205-2215(2018).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
Mob. DNA 7:20.1-20.11(2016).
Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
Maughan T.S., Ryan A.J.
Oncotarget 7:60807-60822(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Vandesompele J.
Sci. Data 3:160052-160052(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Human biosample authentication using the high-throughput, cost-effective SNPtrace(TM) system.
Bourgon R., Neve R.M.
PLoS ONE 10:E0116218-E0116218(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.
Shibata H., Ito T., Baba Y., Baba H.
Oncol. Lett. 8:1025-1030(2014).
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
PLoS ONE 9:E92047-E92047(2014).
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Hirshfield K.M., Oltvai Z.N., Vazquez A.
Cancer Metab. 1:20.1-20.13(2013).
Reconstructing targetable pathways in lung cancer by integrating diverse omics data.
Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.
Nat. Commun. 4:2617.1-2617.13(2013).
Global proteome analysis of the NCI-60 cell line panel.";
Wilhelm M., Kuster B.
Cell Rep. 4:609-620(2013).
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Gazdar A.F.
Oncogene 7:171-180(1992).
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
Linnoila R.I.
Oncogene 7:743-749(1992).
Novel antigens characteristic of neuroendocrine malignancies.";
Boerman O.C., Ramaekers F.C.S.
Cancer 67:619-633(1991).
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
J. Natl. Cancer Inst. 83:757-766(1991).
Spontaneous changes in intermediate filament protein expression patterns in lung cancer cell lines.
Carney D.N., Vooijs G.P., Ramaekers F.C.S.
J. Cell Sci. 91:91-108(1988).
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.
Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.
Cancer Res. 46:798-806(1986).
Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.
Mitchell J.B.
J. Natl. Cancer Inst. 73:801-807(1984).
Monoclonal antibodies that demonstrate specificity for several types of human lung cancer.
Cuttitta F., Rosen S.T., Gazdar A.F., Minna J.D.
Proc. Natl. Acad. Sci. U.S.A. 78:4591-4595(1981).
High levels of intracellular bombesin characterize human small-cell lung carcinoma.
Moody T.W., Pert C.B., Gazdar A.F., Carney D.N., Minna J.D.
Science 214:1246-1248(1981).
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.
van Zijl P.L.
Eur. J. Cancer 31A:230-237(1995).
Insulin-like growth factor expression in human cancer cell lines.";
Grimley C., Battey J., Mulshine J.L., Cuttitta F.
J. Biol. Chem. 271:11477-11483(1996).
NCI-Navy Medical Oncology Branch cell line data base.";
Carney D.N., Minna J.D., Mulshine J.L.
J. Cell. Biochem. Suppl. 24:32-91(1996).
Establishment of a drug sensitivity panel using human lung cancer cell lines.
Kohara H., Harada M.
Acta Med. Okayama 53:67-75(1999).
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Int. J. Oncol. 15:927-934(1999).
Systematic variation in gene expression patterns in human cancer cell lines.
Botstein D., Brown P.O.
Nat. Genet. 24:227-235(2000).
Mutation and expression of the DCC gene in human lung cancer.";
Yokota J.
Neoplasia 2:300-305(2000).
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Oncogene 19:4632-4639(2000).
p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer.
Wagenius G.
Anticancer Res. 23:1207-1212(2003).
Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H., Oguri T., Sato S., Maeda H., Niimi T., Ueda R.
Cancer Sci. 95:753-757(2004).
HLA class I and II genotype of the NCI-60 cell lines.";
Morse H.C. 3rd, Stroncek D., Marincola F.M.
J. Transl. Med. 3:11.1-11.8(2005).
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
Tomoda H., Yamori T., Tsuruo T.
J. Natl. Cancer Inst. 97:765-777(2005).
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mol. Cancer Ther. 5:2606-2612(2006).
The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer.
Cigudosa J.C., Lazo P.A., Sanchez-Cespedes M.
Hum. Mol. Genet. 18:1343-1352(2009).
DNA fingerprinting of the NCI-60 cell line panel.";
Chanock S.J., Weinstein J.N.
Mol. Cancer Ther. 8:713-724(2009).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Kong D.-X., Yamori T.
Bioorg. Med. Chem. 20:1947-1951(2012).
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
PLoS ONE 7:E31628-E31628(2012).
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
Yoon C.N., Chang Y.-T.
PLoS ONE 7:E32096-E32096(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Science 336:1040-1044(2012).
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Heymach J.V.
Cancer Discov. 2:798-811(2012).